stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / CYTK / Revenue

Cytokinetics, Incorporated Revenue 1999–2025

Cytokinetics, Incorporated (CYTK) annual revenue by fiscal year, computed from SEC filings.

Fiscal yearRevenueChange (YoY)
FY 2025$88.04M+376.6%
FY 2024$18.47M+145.3%
FY 2023$7.53M-92.0%
FY 2022$94.59M+34.3%
FY 2021$70.43M+26.2%
FY 2020$55.83M+107.8%
FY 2019$26.87M-14.7%
FY 2018$31.50M+135.6%
FY 2017$13.37M-87.4%
FY 2016$106.41M+271.3%
FY 2015$28.66M-38.9%
FY 2014$46.94M+53.2%
FY 2013$30.65M+305.5%
FY 2012$7.56M+89.0%
FY 2011$4.00M+55.2%
FY 2010$2.58M-96.8%
FY 2009$81.54M
FY 2008$0
FY 2007$0
FY 2006$0
FY 2005$0
FY 2004$0
FY 2003$0
FY 2002$0
FY 2001$0
FY 2000$0
FY 1999$0

Source: Cytokinetics, Incorporated SEC filings — income statement (10-K). Refreshed nightly.

See the full picture for Cytokinetics, Incorporated

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Cytokinetics, Incorporated — frequently asked questions

What is Cytokinetics, Incorporated's revenue?

Cytokinetics, Incorporated (CYTK) reported revenue of $88.04M for fiscal year 2025, per its SEC filings.

Where does this data come from?

Figures are computed from Cytokinetics, Incorporated's official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.

More CYTK financial history

Full CYTK fundamentals page → · All 1,500+ companies →